GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Research & Development

Huakang Biomedical Holdings Co (HKSE:08622) Research & Development : HK$1.03 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Huakang Biomedical Holdings Co's Research & Development for the three months ended in Dec. 2024 was HK$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1.03 Mil.


Huakang Biomedical Holdings Co Research & Development Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Research & Development Chart

Huakang Biomedical Holdings Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.67 2.98 2.77 2.79 3.02

Huakang Biomedical Holdings Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.89 0.14 - -

Huakang Biomedical Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huakang Biomedical Holdings Co  (HKSE:08622) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Huakang Biomedical Holdings Co Research & Development Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Huakang Biomedical Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.
Executives
Yu Chi Mau 2106 Person having a security interest in shares
Li King Yeung 2106 Person having a security interest in shares
Crystal Grant Limited 2101 Beneficial owner
Arena Investment Management (singapore) Pte Ltd 2102 Investment manager
Arena Investors, Lp 2102 Investment manager
Arena Sg Spv I, Llc 2201 Interest of corporation controlled by you
Tgga, Llc 2106 Person having a security interest in shares
Lau Lai Yee 2201 Interest of corporation controlled by you
Kokusai Resources Company Limited 2101 Beneficial owner
Zhang Shuguang 2101 Beneficial owner
Chang Yim Yang 2401 A concert party to an agreement to buy shares
Ever Charming Inc. 2101 Beneficial owner
Wealthy Pride Investment Limited 2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines